Controlling protein transport by small molecules

Current Drug Targets

Volumn 12, Issue 11, 2011, Pages 1574-1580

  Gademann, Karl ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Anticancer compounds; Cell biology; Chemical biology; Natural products; Nuclear export

Indexed keywords

1' ACETOXYCHAVICOL ACETATE; ANGUINOMYCIN; ANGUINOMYCIN C; ANGUINOMYCIN D; ANTINEOPLASTIC AGENT; DIDROVALTRATE; EXPORTIN 1; GONIOTHALAMIN; JBIR 02; LEPTOMYCIN B; LEUCINE; NATURAL PRODUCT; PEUMUSOLIDE A; UNCLASSIFIED DRUG; VALTRATE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL NUCLEUS; CYTOPLASM; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; NUCLEAR EXPORT SIGNAL; NUCLEOCYTOPLASMIC TRANSPORT; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; STRUCTURE ACTIVITY RELATION;

CELL NUCLEUS; MODELS, MOLECULAR; NUCLEAR EXPORT SIGNALS; PROTEIN TRANSPORT;

EID: 80054084048     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945011798109446     Document Type: Article

References (56)

1. Cragg GM, Grothaus PG, Newman DJ. Impact of natural products on developing new anti-cancer agents. Chem Rev 2009; 109(7): 3012-43.
2. Schreiber SL. Chemical genetics resulting from a passion for synthetic organic chemistry. Bioorgan Med Chem 1998; 6(8): 1127-52.
3. Hubel K, Lessmann T, Waldmann H. Chemical biology - identification of small molecule modulators of cellular activity by natural product inspired synthesis. Chem Soc Rev 2008; 37(7): 1361-74.
4. Bialy L, Waldmann H. Inhibitors of protein tyrosine phosphatases: next-generation drugs? Angew Chem Int Ed 2005; 44(25): 3814-39.
5. Görlich D, Mattaj IW. Protein kinesis - nucleocytoplasmic transport. Science 1996; 271(5255): 1513-8.
6. Rothman JE. Mechanism of intracellular protein transport. Nature 1994; 372(6501): 55-63.
7. Görlich D, Kutay U. Transport between the cell nucleus and the cytoplasm. Ann Rev Cell Develop Biol 1999; 15: 607-60.
8. Ohno M, Fornerod M, Mattaj IW. Nucleocytoplasmic transport: the last 200 nanometers. Cell 1998; 92(3): 327-36.
9. Mattaj IW, Englmeier L. Nucleocytoplasmic transport: the soluble phase. Ann Rev Biochem 1998; 67: 265-306.
10. Nigg EA. Nucleocytoplasmic transport: signals, mechanisms and regulation. Nature 1997; 386(6627): 779-87.
11. Mansfeld J, Güttinger S, Hawryluk-Gara LA, et al. The conserved transmembrane nucleoporin NDC1 is required for nuclear pore complex assembly in vertebrate cells. Mol Cell 2006; 22(1): 93-103.
12. Güttinger S, Muhlhausser P, Koller-Eichhorn R, Brennecke J, Kutay U. Transportin2 functions as importin and mediates nuclear import of HuR. P Natl Acad Sci USA 2004; 101(9): 2918-23.
13. OssarehNazari B, Bachelerie F, Dargemont C. Evidence for a role of CRM1 in signal-mediated nuclear protein export. Science 1997; 278(5335): 141-4.
14. Fukuda M, Asano S, Nakamura T, et al. CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature 1997; 390(6657): 308-11.
15. Fornerod M, Ohno M, Yoshida M, Mattaj IW. CRM1 is an export receptor for leucine-rich nuclear export signals. Cell 1997; 90(6): 1051-60.
16. Kutay U, Güttinger S. Leucine-rich nuclear-export signals: born to be weak. Trends Cell Biol 2005; 15(3): 121-4.
17. Kalesse M, Christmann M. The chemistry and biology of the leptomycin family. Synthesis-Stuttgart 2002; (8): 981-1003.
18. Yashiroda Y, Yoshida M. Nucleo-cytoplasmic transport of proteins as a target for therapeutic drugs. Curr Med Chem 2003; 10(9): 741-8.
19. Dong XH, Biswas A, Suel KE, et al. Structural basis for leucine- rich nuclear export signal recognition by CRM1. Nature 2009; 458(7242): 1136-41.
20. Dong XH, Biswas A, Chook YM. Structural basis for assembly and disassembly of the CRM1 nuclear export complex. Nat Struct Mol Biol 2009; 16(5): 558-60.
21. Monecke T, Guttler T, Neumann P, Dickmanns A, Görlich D, Ficner R. Crystal structure of the nuclear export receptor CRM1 in complex with Snurportin1 and RanGTP. Science 2009; 324(5930): 1087-91.
22. Kudo N, Matsumori N, Taoka H, et al. Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc Natl Acad Sci USA 1999; 96(16): 9112-7.
23. Kudo N, Wolff B, Sekimoto T, et al. Leptomycin B inhibition of signal-mediated nuclear export by direct binding to CRM1. Exper Cell Res 1998; 242(2): 540-7.
24. Bonazzi S, Eidam O, Güttinger S, et al. Anguinomycins and derivatives: total Syntheses, modeling, and biological evaluation of the inhibition of nucleocytoplasmic transport. J Am Chem Soc 2010; 132(4): 1432-42.
25. Wolff B, Sanglier JJ, Wang Y. Leptomycin B is an inhibitor of nuclear export: inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev-dependent mRNA. Chem Biol 1997; 4(2): 139-47.
26. Nishi K, Yoshida M, Fujiwara D, Nishikawa M, Horinouchi S, Beppu T. Leptomycin B targets a regulatory cascade of CRM1, a fission yeast nuclear protein, involved in control of higher-order chromosome structure and gene-expression. J Biol Chem 1994; 269(9): 6320-4.
27. Hayakawa Y, Sohda K, Shinya K, Hidaka T, Seto H. Anguinomycin-C and Anguinomycin D, new antitumor antibiotics with selective cytotoxicity against transformed cells. J Antibiot 1995; 48(9): 954-61.
28. Hayakawa Y, Adachi K, Komeshima N. New Antitumor Antibiotics, Anguinomycin-A and Anguinomycin-B. J Antibiot 1987; 40(9): 1349-52.
29. Bonazzi S, Binaghi M, Fellay C, Wach JY, Gademann K. Synthetic studies on the sporolides: exploration of the enediyne route. Synthesis-Stuttgart 2010; (4): 631-42.
30. Bonazzi S, Barbaras D, Patiny L, et al. Antimalarial and antitubercular nostocarboline and eudistomin derivatives: synthesis, in vitro and in vivo biological evaluation. Bioorgan Med Chem 2010; 18(4): 1464-76.
31. Wach JY, Gademann K. Enantioselective synthesis of the sporolide quinone acid fragment. Synlett 2009; (17): 2849-51.
32. Jessen HJ, Barbaras D, Hamburger M, Gademann K. Total synthesis and neuritotrophic activity of Farinosone C and derivatives. Org Lett 2009; 11(15): 3446-9.
33. Gademann K, Portmann C. Secondary metabolites from cyanobacteria: complex structures and powerful bioactivities. Curr Org Chem 2008; 12(4): 326-41.
34. Gademann K, Bethuel Y, Locher HH, Hubschwerlen C. Biomimetic total synthesis and antimicrobial evaluation of anachelin H. J Org Chem 2007; 72: 8361-70.
35. Gademann K, Bethuel Y. Total synthesis of anachelin H. Org Lett 2004; 6(25): 4707-10.
36. Gademann K, Bethuel Y. A biomimetic route to the peptide alkaloid anachelin. Angew Chem Int Ed 2004; 43(25): 3327-9.
37. Bonazzi S, Güttinger S, Zemp I, Kutay U, Gademann K. Total synthesis, configuration, and biological evaluation of anguinomycin C. Angew Chem Int Ed 2007; 46(45): 8707-10.
38. Jewers K, Blunden G, Wetchapi S, et al. Goniothalamin and its distribution in 4 Goniothalamus species. Phytochem 1972; 11(6): 2025-30.
39. Inayat-Hussain SH, Chan KM, Rajab NF, et al. Goniothalamin- induced oxidative stress, DNA damage and apoptosis via caspase-2 independent and Bcl-2 independent pathways in Jurkat T-cells. Toxicol Lett 2010; 193(1): 108-14.
40. Martins CVB, de Resende MA, da Silva DL, et al. In vitro studies of anticandidal activity of goniothalamin enantiomers. J Appl Microbiol 2009; 107(4): 1279-86.
41. Senthil-Nathan S, Choi MY, Paik CH, Kalaivani K. The toxicity and physiological effect of goniothalamin, a styryl-pyrone, on the generalist herbivore, Spodoptera exigua Hubner. Chemosphere 2008; 72(9): 1393-400.
42. Martins CVB, de Resende MA, Magalhaes TFF, et al. Antifungal activity of goniothalamin enantiomers. Lett Drug Des Discov 2008; 5(1): 74-8.
43. de Fatima A, Zambuzzi WF, Modolo LV, et al. Cytotoxicity of goniothalamin enantiomers in renal cancer cells: involvement of nitric oxide, apoptosis and autophagy. Chemico-Biological Interactions 2008; 176(2-3): 143-50.
44. Wach JY, Güttinger S, Kutay U, Gademann K. The cytotoxic styryl lactone goniothalamin is an inhibitor of nucleocytoplasmic transport. Bioorg Med Chem Lett 2010; 20(9): 2843-6.
45. Ueda JY, Togashi T, Matukura S, et al. A novel nuclear export inhibitor JBIR-02, a new piericidin discovered from streptomyces sp ML55. J Antibiot 2007; 60: 459-62.
46. Thies PW. Constitution of Valepotriates. report of active agents of Valerian. Tetrahedron 1968; 24(1): 313-47.
47. Murakami N, Ye Y, Kawanishi M, et al. New Rev-transport inhibitor with anti-HIV activity from Valerianae Radix. Bioorg Med Chem Lett 2002; 12(20): 2807-10.
48. Tamura S, Shimizu N, Fujiwara K, Kaneko M, Kimura T, Murakami N. Bioisostere of valtrate, anti-HIV principle by inhibition for nuclear export of Rev. Bioorg Med Chem Lett 2010; 20(7): 2159-62.
49. Tamura S, Shiomi A, Kaneko M, et al. New Rev-export inhibitor from Alpinia galanga and structure-activity relationship. Bioorg Med Chem Lett 2009; 19(9): 2555-7.
50. Tamura S, Shiomi A, Kimura T, Murakami N. Halogenated analogs of 1 '-acetoxychavicol acetate, Rev-export inhibitor from Alpinia galanga, designed from mechanism of action. Bioorg Med Chem Lett 2010; 20(7): 2082-5.
51. Tamura S, Hattori Y, Kaneko M, et al. Peumusolide A, unprecedented NES non-antagonistic inhibitor for nuclear export of MEK. Tetrahedron Lett 2010; 51(13): 1678-81.
52. Tamura S, Kaneko M, Shiomi A, Yang GM, Yamaura T, Murakami N. Unprecedented NES non-antagonistic inhibitor for nuclear export of Rev from Sida cordifolia. Bioorg Med Chem Lett 2010; 20(6): 1837-9.
53. Kau TR, Schroeder F, Ramaswamy S, et al. A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell 2003; 4(6): 463-76.
54. Daelemans D, Afonina E, Nilsson J, et al. A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export. Proc Natl Acad Sci USA 2002; 99(22): 14440-5.
55. Van Neck T, Pannecouque C, Vanstreels E, Stevens M, Dehaen W, Daelemans D. Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: structure-activity relationship and mechanism of action. Bioorgan Med Chem 2008; 16(21): 9487-97.
56. Monovich L, Koch KA, Burgis R, et al. Suppression of HDAC nuclear export and cardiomyocyte hypertrophy by novel irreversible inhibitors of CRM1. Biochimica Et Biophysica Acta- Gene Regulatory Mechanisms 2009; 1789(5): 422-31.